Lord, Abbett & Co
BDTX icon

Lord, Abbett & Co’s Black Diamond Therapeutics BDTX Stock Holding History

Lord, Abbett & Co’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-261,918
Closed -$8.39M – 640
2020
Q4 		$8.39M Buy
261,918
+108,067
+70% +$3.55M 0.02% 554
2020
Q3 		$4.65M Sell
153,851
-9,933
-6% -$302K 0.01% 572
2020
Q2 		$6.91M Buy
163,784
+26,052
+19% +$959K 0.02% 529
2020
Q1 		$3.44M Buy
+137,732
New +$4.19M 0.02% 569

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Lord, Abbett & Co's BDTX Position: Q1 2021 in Review

Lord, Abbett & Co sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 261,918 shares — an estimated $8.39M sold.

Lord, Abbett & Co first reported a position in BDTX in Q1 2020 and held it in 4 quarters. The position peaked at $8.39M in Q4 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

  • Lord, Abbett & Co reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 261,918 Black Diamond Therapeutics shares in Q1 2021, an estimated $8.39M.
  • Lord, Abbett & Co first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 4 quarters.
  • Lord, Abbett & Co's Black Diamond Therapeutics position peaked at $8.39M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.